S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well erlotinib works in treating patients with advanced
primary non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking
the enzymes necessary for their growth